Toni K. Choueiri
M.D.

Dr. Choueiri is the director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and medical director of international strategic initiatives and past president of the medical staff at Dana-Farber . He is also an elected member of the American Society of Clinical Investigation (ASCI) and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He serves on the KidneyCan Board, American Society of Clinical Oncology (ASCO) Board, the National Cancer Institute (NCI) GU Steering Committee and is a member of the U.S. FDA’s Oncologic Drugs Advisory Committee. Dr. Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of kidney cancer and led to the approval of several therapies. He has over 800 PubMed-indexed publications involving GU cancers, drug development and biomarkers. He is the lead investigator of multiple national and international Phase 1-3 trials in GU cancers. His laboratory work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.

Dr. Choueiri completed his M.D. training at Saint Joseph University Faculté de Medicine, residency in Internal Medicine and fellowship in hematology/medical oncology at Cleveland Clinic. He is board certified in medical oncology.